Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Francis Berenbaum,Francisco J. Blanco,Ali Guermazi,Kenji Miki,Takaharu Yamabe,Lars Viktrup,Rod Junor,William Carey,Mark T. Brown,Christine R. West,Kenneth M. Verburg +10 more
Reads0
Chats0
TLDR
Tanezumab 5 mg statistically significantly improved pain, physical function and PGA-OA, but tanezumsumab 2.5mg only achieved two co-primary end points, but there was a statistically significant improvement in WOMAC Pain and Physical Function, but not PGA -OA.Abstract:
Objective Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up. Methods This double-blind, randomised, phase III study enrolled adults in Europe and Japan with moderate-to-severe OA who had not responded to or could not tolerate standard-of-care analgesics. Patients were randomised to tanezumab 2.5 mg or 5 mg subcutaneously or matching placebo every 8 weeks (three doses). Co-primary end points were change from baseline to week 24 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Physical Function, and Patient’s Global Assessment of OA (PGA-OA). Joint safety and neurological assessments continued throughout the 48-week study. Results From March 2016 to December 2017, 849 patients were randomised and evaluated (placebo n=282, tanezumab 2.5 mg n=283, tanezumab 5 mg n=284). At week 24, there was a statistically significant improvement from baseline for tanezumab 5 mg compared with placebo for WOMAC Pain (least squares mean difference±SE –0.62±0.18, p=0.0006), WOMAC Physical Function (–0.71±0.17, p Conclusion Tanezumab 5 mg statistically significantly improved pain, physical function and PGA-OA, but tanezumab 2.5 mg only achieved two co-primary end points. RPOA occurred more frequently with tanezumab 5 mg than tanezumab 2.5 mg. TJRs were similarly distributed across all three groups. Trial registration number NCT02709486.read more
Citations
More filters
Journal ArticleDOI
Antibodies to watch in 2021.
Hélène Kaplon,Janice M. Reichert +1 more
TL;DR: In this paper, the authors discuss key events in antibody therapeutics development that occurred in 2020 and forecast events that might occur in 2021, including the coronavirus disease 2019 (COVID-19) pandemic.
Journal ArticleDOI
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Emanuel Della-Torre,Corrado Campochiaro,Giulio Cavalli,Giacomo De Luca,Angela Napolitano,Salvatore La Marca,Nicola Boffini,Valentina Da Prat,Gaetano Di Terlizzi,Marco Lanzillotta,Patrizia Rovere Querini,Annalisa Ruggeri,Giovanni Landoni,Moreno Tresoldi,Fabio Ciceri,Alberto Zangrillo,Francesco De Cobelli,Lorenzo Dagna +17 more
TL;DR: Overall clinical improvement and mortality in patients with severe COVID-19 pneumonia were not significantly different between sarilumab and standard of care and Sariluab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline.
Journal ArticleDOI
Emerging pharmaceutical therapies for osteoarthritis.
TL;DR: The pathophysiological targets and clinical effects of new drugs currently being investigated for the treatment of osteoarthritis, along with relevant clinical data and discussion of the main challenges for the further development of these therapies are described to provide context for the latest advances in the field of pharmaceutical therapies for OA.
Journal ArticleDOI
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
Hendrik Schulze-Koops,Klaus Krueger,Inka Vallbracht Vallbracht,Rebecca Hasseli,Alla Skapenko +4 more
TL;DR: Accumulating data suggest that baseline use of bDMARDs is not associated with worse COVID-19 outcome and that some caution may have to be applied when employing rituximab (RTX), a B-cell depleting b DMARD, in patients with immune-mediated disease.
Journal ArticleDOI
The evolution of nerve growth factor inhibition in clinical medicine.
TL;DR: Anti-NGF antibody treatments, if approved, should reduce pain and improve quality of life for individuals with knee and hip OA; however, safety monitoring programmes will be necessary.
References
More filters
Book
Statistical Power Analysis for the Behavioral Sciences
TL;DR: The concepts of power analysis are discussed in this paper, where Chi-square Tests for Goodness of Fit and Contingency Tables, t-Test for Means, and Sign Test are used.
Journal ArticleDOI
Radiological Assessment of Osteo-Arthrosis
J. H. Kellgren,J. S. Lawrence +1 more
TL;DR: It was concluded that, to ensure maximum uniformity in grading x rays in field surveys and therapeutic trials, all readings should be made by the same observer, preferably at a single session.
Journal ArticleDOI
Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee
Roy D. Altman,E. Asch,Daniel Bloch,Giles G. Bole,David G. Borenstein,Kenneth D. Brandt,Wallace C. Christy,Cooke Td,Robert A. Greenwald,Marc C. Hochberg,David S. Howell,David L. Kaplan,William J. Koopman,Selden Longley,Henry J. Mankin,Dennis J. McShane,Thomas A. Medsger,Robert F. Meenan,William M. Mikkelsen,Roland W. Moskowitz,William A. Murphy,B. Rothschild,Mark R. Segal,Leon Sokoloff,Frederick Wolfe +24 more
TL;DR: Variables from the medical history, physical examination, laboratory tests, and radiographs were used to develop sets of criteria that serve different investigative purposes and these proposed criteria utilize classification trees, or algorithms.
Journal ArticleDOI
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee
Marc C. Hochberg,Roy D. Altman,Karine Toupin April,Maria Benkhalti,Gordon H. Guyatt,Jessie McGowan,Tanveer Towheed,Vivian Welch,George A. Wells,Peter Tugwell +9 more
TL;DR: To update the American College of Rheumatology (ACR) 2000 recommendations for hip and knee osteoarthritis (OA) and develop new recommendations for hand OA.
Journal ArticleDOI
Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations
Robert H. Dworkin,Dennis C. Turk,Kathleen W. Wyrwich,Dorcas E. Beaton,Charles S. Cleeland,John T. Farrar,Jennifer A. Haythornthwaite,Mark P. Jensen,Robert D. Kerns,Deborah N. Ader,Nancy A. Brandenburg,Laurie B. Burke,David Cella,Julie Chandler,Penny Cowan,Rozalina Dimitrova,Raymond A. Dionne,Sharon Hertz,Alejandro R. Jadad,Nathaniel P. Katz,Henrik Kehlet,Lynn D. Kramer,Donald C. Manning,Cynthia McCormick,Michael P. McDermott,Henry J McQuay,Sanjay Patel,Linda Porter,Steve Quessy,Bob A. Rappaport,Christine Rauschkolb,Dennis A. Revicki,Margaret Rothman,Kenneth E. Schmader,Brett R. Stacey,Joseph W. Stauffer,Thorsten von Stein,Richard E. White,James Witter,Stojan Zavisic +39 more
TL;DR: A consensus meeting was convened by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to provide recommendations for interpreting clinical importance of treatment outcomes in clinical trials of the efficacy and effectiveness of chronic pain treatments as discussed by the authors.